デフォルト表紙
市場調査レポート
商品コード
989812

生物製剤市場規模調査:製品別、用途別(~2026年)、COVID-19の累積的影響

Biologics Market Research Report by Product, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.01円
生物製剤市場規模調査:製品別、用途別(~2026年)、COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の生物製剤の市場規模は、2020年の2462億7201万米ドルから、2025年末までに3048億6647万米ドルに成長すると予想されています。

市場セグメンテーションとカバレッジ:

当調査は、生物製剤の世界市場を分類して、収益を予測し、次の各サブマーケットの動向を分析します。

製品別だと、生物製剤市場は、細胞ベースの生物製剤、遺伝子ベースの生物製剤、モノクローナル抗体、組換えホルモン/タンパク質、およびワクチンにわたって調査されました。

用途別だと、生物学的製剤市場は、自己免疫疾患、癌、感染症、および希少疾患にわたって調査されました。

地域別だと、生物製剤市場は南北アメリカ、アジア太平洋、欧州、中東・アフリカで調査されました。

COVID-19の累積的影響:

COVID-19は、ほぼすべての業界に影響を与えた比類のない世界的な公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されます。私たちの進行中の調査は、調査フレームワークを増幅して、基礎となるCOVID-19の問題と今後の潜在的な道筋を確実に含めるようにしています。調査は消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場の力のダイナミクス、および政府の重要な介入を考慮したCOVID-19に関する洞察を提供しています。更新された調査は、市場へのCOVID-19の影響を考慮して、洞察、分析、推定、および予測を提供します。

レポートは、次の指針に関する洞察を提供します。

  • 1.市場浸透:主要なプレーヤーにより提供される市場に関する包括的な情報
  • 2.市場開発:収益性の高い新興市場に関する詳細な情報と市場分析
  • 3.市場の多様化:新製品の発売、未開発の地域、最近の開発、および投資に関する詳細情報
  • 4.競争力のある評価とインテリジェンス:主要企業の市場シェア、戦略、製品、製造能力の徹底的な評価を提供します
  • 5.製品開発とイノベーション:将来のテクノロジー、R&D活動、および新製品開発に関する洞察

レポートは次のような質問に答えます。

1.世界の生物製剤市場の市場規模と予測はどのくらいですか?

2.予測期間中に世界の生物製剤市場を形成するCOVID-19の阻害要因と影響は何ですか?

3.世界の生物製剤市場の予測期間中に投資する製品/セグメント/用途/領域はどれですか?

4.世界の生物製剤市場における機会の競争戦略ウィンドウは何ですか?

5.世界の生物製剤市場動向技術動向と規制の枠組みは何ですか?

6.世界の生物製剤市場に参入するのに適していると考えられるモードと戦略的動きは何ですか?

当レポートでは、生物製剤市場を調査し、市場概要、市場の成長要因および阻害要因の分析、製品別、用途別、地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイル、市場機会など、包括的な情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画を作成する
    • 実行:調査を実施する
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • 製品別の見通し
  • 用途別の見通し
  • 地域別の見通し
  • 競合他社別の見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 製品別の世界の生物製剤市場

  • イントロダクション
  • 細胞生物製剤
  • 遺伝子生物製剤
  • モノクローナル抗体
  • 組換えホルモン/タンパク質
  • ワクチン

第7章 用途別の世界の生物製剤市場

  • イントロダクション
  • 自己免疫疾患
  • 感染症
  • 希少疾患

第8章 南北アメリカの生物製剤市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の生物製剤市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第10章 欧州・中東・アフリカの生物製剤市場

  • イントロダクション
  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第12章 企業のユーザビリティプロファイル

  • AbbVie Inc.
  • Amgen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA

第13章 付録

  • ディスカッションガイド
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS MARKET SIZE, 2020 VS 2026 (USD BILLION)
  • FIGURE 2. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2020 (USD BILLION)
  • FIGURE 3. GLOBAL BIOLOGICS MARKET SIZE, BY APPLICATION, 2020 (USD BILLION)
  • FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
  • FIGURE 5. GLOBAL BIOLOGICS MARKET: MARKET DYNAMICS
  • FIGURE 6. GLOBAL BIOLOGICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2020 VS 2026 (%)
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2020 VS 2026 (USD BILLION)
  • FIGURE 9. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2026
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY CELLULAR BASED BIOLOGICS, 2018-2026 (USD BILLION)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY CELLULAR BASED BIOLOGICS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY GENE BASED BIOLOGICS, 2018-2026 (USD BILLION)
  • FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY GENE BASED BIOLOGICS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 14. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2026 (USD BILLION)
  • FIGURE 15. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 16. GLOBAL BIOLOGICS MARKET SIZE, BY DIAGNOSTIC, 2018-2026 (USD BILLION)
  • FIGURE 17. GLOBAL BIOLOGICS MARKET SIZE, BY DIAGNOSTIC, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 18. GLOBAL BIOLOGICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, 2018-2026 (USD BILLION)
  • FIGURE 19. GLOBAL BIOLOGICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 20. GLOBAL BIOLOGICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2026 (USD BILLION)
  • FIGURE 21. GLOBAL BIOLOGICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 22. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC, 2018-2026 (USD BILLION)
  • FIGURE 23. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 24. GLOBAL BIOLOGICS MARKET SIZE, BY DIRECT MAB AGENTS, 2018-2026 (USD BILLION)
  • FIGURE 25. GLOBAL BIOLOGICS MARKET SIZE, BY DIRECT MAB AGENTS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 26. GLOBAL BIOLOGICS MARKET SIZE, BY TARGETING MAB AGENTS, 2018-2026 (USD BILLION)
  • FIGURE 27. GLOBAL BIOLOGICS MARKET SIZE, BY TARGETING MAB AGENTS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 28. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT HORMONES/PROTEINS, 2018-2026 (USD BILLION)
  • FIGURE 29. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT HORMONES/PROTEINS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 30. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2026 (USD BILLION)
  • FIGURE 31. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 32. GLOBAL BIOLOGICS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
  • FIGURE 33. GLOBAL BIOLOGICS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD BILLION)
  • FIGURE 34. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOLOGICS MARKET SIZE, BY APPLICATION, 2026
  • FIGURE 35. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2026 (USD BILLION)
  • FIGURE 36. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 37. GLOBAL BIOLOGICS MARKET SIZE, BY CANCER, 2018-2026 (USD BILLION)
  • FIGURE 38. GLOBAL BIOLOGICS MARKET SIZE, BY CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 39. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2026 (USD BILLION)
  • FIGURE 40. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 41. GLOBAL BIOLOGICS MARKET SIZE, BY RARE DISEASES, 2018-2026 (USD BILLION)
  • FIGURE 42. GLOBAL BIOLOGICS MARKET SIZE, BY RARE DISEASES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 43. AMERICAS BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 44. AMERICAS BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 46. ARGENTINA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 47. BRAZIL BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 48. CANADA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 49. MEXICO BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 50. UNITED STATES BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 51. CALIFORNIA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 52. FLORIDA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 53. ILLINOIS BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 54. NEW YORK BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 55. OHIO BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 56. PENNSYLVANIA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 57. TEXAS BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 58. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 59. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 60. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 61. CHINA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 62. INDIA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 63. INDONESIA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 64. JAPAN BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 65. MALAYSIA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 66. PHILIPPINES BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 67. SOUTH KOREA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 68. THAILAND BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 69. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 70. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 71. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 72. FRANCE BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 73. GERMANY BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 74. ITALY BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 75. NETHERLANDS BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 76. QATAR BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 77. RUSSIA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 78. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 79. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 80. SPAIN BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 81. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 82. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 83. GLOBAL BIOLOGICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 84. GLOBAL BIOLOGICS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 85. GLOBAL BIOLOGICS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 86. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOLOGICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY CELLULAR BASED BIOLOGICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY GENE BASED BIOLOGICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY DIAGNOSTIC, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY DIRECT MAB AGENTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY TARGETING MAB AGENTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT HORMONES/PROTEINS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY RARE DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 20. AMERICAS BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 21. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 22. AMERICAS BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 23. ARGENTINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 24. ARGENTINA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 25. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 26. BRAZIL BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 27. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 28. CANADA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 29. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 30. MEXICO BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 31. UNITED STATES BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 32. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 33. UNITED STATES BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 34. CALIFORNIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 35. CALIFORNIA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 36. FLORIDA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 37. FLORIDA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 38. ILLINOIS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 39. ILLINOIS BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 40. NEW YORK BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 41. NEW YORK BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 42. OHIO BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 43. OHIO BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 44. PENNSYLVANIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 45. PENNSYLVANIA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 46. TEXAS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 47. TEXAS BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 48. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 49. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 50. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 51. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 52. CHINA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 53. INDIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 54. INDIA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 55. INDONESIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 56. INDONESIA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 57. JAPAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 58. JAPAN BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 59. MALAYSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 60. MALAYSIA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 61. PHILIPPINES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 62. PHILIPPINES BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 63. SOUTH KOREA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 64. SOUTH KOREA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 65. THAILAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 66. THAILAND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 70. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 71. FRANCE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 72. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 73. GERMANY BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 74. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 75. ITALY BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 76. NETHERLANDS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 77. NETHERLANDS BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 78. QATAR BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 79. QATAR BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 80. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 81. RUSSIA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 82. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 83. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 84. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 85. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 86. SPAIN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 87. SPAIN BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 88. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 89. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 90. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 91. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 92. GLOBAL BIOLOGICS MARKET: SCORES
  • TABLE 93. GLOBAL BIOLOGICS MARKET: BUSINESS STRATEGY
  • TABLE 94. GLOBAL BIOLOGICS MARKET: PRODUCT SATISFACTION
  • TABLE 95. GLOBAL BIOLOGICS MARKET: RANKING
  • TABLE 96. GLOBAL BIOLOGICS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 97. GLOBAL BIOLOGICS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 98. GLOBAL BIOLOGICS MARKET: MERGER & ACQUISITION
  • TABLE 99. GLOBAL BIOLOGICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 100. GLOBAL BIOLOGICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 101. GLOBAL BIOLOGICS MARKET: INVESTMENT & FUNDING
  • TABLE 102. GLOBAL BIOLOGICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 103. GLOBAL BIOLOGICS MARKET: LICENSE & PRICING
  • TABLE 104. GLOBAL BIOLOGICS MARKET: CONTACT DETAILS
目次
Product Code: MRR-4302AC722017

The Global Biologics Market size was estimated at USD 247.82 Billion in 2020 and expected to reach USD 259.87 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 5.19% to reach USD 335.91 Billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Biologics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the Biologics Market was studied across Cellular Based Biologics, Gene Based Biologics, Monoclonal Antibodies, Recombinant Hormones/Proteins, and Vaccines. The Monoclonal Antibodies is further studied across Diagnostic and Therapeutic.

Based on Application, the Biologics Market was studied across Autoimmune Diseases, Cancer, Infectious Diseases, and Rare Diseases.

Based on Geography, the Biologics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biologics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biologics Market, including AbbVie Inc., Allergan, Amgen Inc, Apogenix, AstraZeneca, Bayer AG, Biocon, BioMarin Pharmaceutical, Celltrion, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gangagen, GlaxoSmithKline PLC, GSK group of companies, Johnson & Johnson, Medexus Pharma, Merck & Co., Novo Nordisk AS, Pfizer Inc., Precision Biologics, Inc., Samsung BioLogics, Sanofi SA, Theratome Bio, Tubulis Technologies, and Vaximm.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Biologics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biologics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biologics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Biologics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Biologics Market?
  • 6. What is the market share of the leading vendors in the Global Biologics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Biologics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Product Outlook
  • 3.4. Application Outlook
  • 3.5. Geography Outlook
  • 3.6. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Attractive investment in the market from players across value chain
      • 5.1.1.2. Rising prevalence of chronic diseases
      • 5.1.1.3. Patent loss of leading biologic drugs
      • 5.1.1.4. Availability of advanced diagnostics and rising government initiatives in healthcare
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory process coupled with high capital investment
    • 5.1.3. Opportunities
      • 5.1.3.1. Higher acceptability for innovative therapies
      • 5.1.3.2. Technological advancements in research and development across the globe
    • 5.1.4. Challenges
      • 5.1.4.1. Tightly controlled atmospheric conditions and maintained production process
      • 5.1.4.2. Cost associated with access of biologics
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Biologics Market, by Product

  • 6.1. Introduction
  • 6.2. Cellular Based Biologics
  • 6.3. Gene Based Biologics
  • 6.4. Monoclonal Antibodies
    • 6.4.1. Diagnostic
      • 6.4.1.1. Biochemical Analysis
      • 6.4.1.2. Diagnostic Imaging
    • 6.4.2. Therapeutic
      • 6.4.2.1. Direct MAB Agents
      • 6.4.2.2. Targeting MAB Agents
  • 6.5. Recombinant Hormones/Proteins
  • 6.6. Vaccines

7. Biologics Market, by Application

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Cancer
  • 7.4. Infectious Diseases
  • 7.5. Rare Diseases

8. Americas Biologics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States
    • 8.6.1. California
    • 8.6.2. Florida
    • 8.6.3. Illinois
    • 8.6.4. New York
    • 8.6.5. Ohio
    • 8.6.6. Pennsylvania
    • 8.6.7. Texas

9. Asia-Pacific Biologics Market

  • 9.1. Introduction
  • 9.2. China
  • 9.3. India
  • 9.4. Indonesia
  • 9.5. Japan
  • 9.6. Malaysia
  • 9.7. Philippines
  • 9.8. South Korea
  • 9.9. Thailand

10. Europe, Middle East & Africa Biologics Market

  • 10.1. Introduction
  • 10.2. France
  • 10.3. Germany
  • 10.4. Italy
  • 10.5. Netherlands
  • 10.6. Qatar
  • 10.7. Russia
  • 10.8. Saudi Arabia
  • 10.9. South Africa
  • 10.10. Spain
  • 10.11. United Arab Emirates
  • 10.12. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
    • 11.1.1. Quadrants
    • 11.1.2. Business Strategy
    • 11.1.3. Product Satisfaction
  • 11.2. Market Ranking Analysis
  • 11.3. Market Share Analysis, By Quadrant
  • 11.4. Market Share Analysis, By Company
  • 11.5. Competitive Scenario
    • 11.5.1. Merger & Acquisition
    • 11.5.2. Agreement, Collaboration, & Partnership
    • 11.5.3. New Product Launch & Enhancement
    • 11.5.4. Investment & Funding
    • 11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles

  • 12.1. AbbVie Inc.
  • 12.2. Allergan
  • 12.3. Amgen Inc
  • 12.4. Apogenix
  • 12.5. AstraZeneca
  • 12.6. Bayer AG
  • 12.7. Biocon
  • 12.8. BioMarin Pharmaceutical
  • 12.9. Celltrion
  • 12.10. Eli Lilly and Company
  • 12.11. F. Hoffmann-La Roche AG
  • 12.12. Gangagen
  • 12.13. GlaxoSmithKline PLC
  • 12.14. GSK group of companies
  • 12.15. Johnson & Johnson
  • 12.16. Medexus Pharma
  • 12.17. Merck & Co.
  • 12.18. Novo Nordisk AS
  • 12.19. Pfizer Inc.
  • 12.20. Precision Biologics, Inc.
  • 12.21. Samsung BioLogics
  • 12.22. Sanofi SA
  • 12.23. Theratome Bio
  • 12.24. Tubulis Technologies
  • 12.25. Vaximm

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
  • 13.3. Contact Details